Cassava Sciences, Inc.

Cassava Sciences Inc. is a biotechnology company focused on developing novel treatments for neurodegenerative diseases. The company's primary purpose is to address unmet medical needs in the treatment of Alzheimer's disease, one of the most challenging and costly conditions worldwide. Cassava Sciences' lead product candidate, simufilam, is aimed at improving both cognitive and behavioral aspects of Alzheimer's, setting it apart in the competitive biotech landscape. In addition to its therapeutic developments, the company is also working on SavaDx, a diagnostic tool intended to detect Alzheimer's through a simple blood test. Headquartered in Austin, Texas, Cassava Sciences leverages innovative research to make significant strides in neuroscience. Its work can significantly impact the healthcare and pharmaceutical industries, offering potential breakthroughs in diagnostics and therapeutics for neurodegenerative diseases. As part of the larger biotech sector, Cassava Sciences plays a crucial role in advancing scientific frontiers and addressing critical health challenges.